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Background: The results of the Iressa in NSCLC for maintenance 
study (NCT00770588; C-TONG 0804), which compared gefitinib 
and placebo as maintenance therapy in patients with advanced 
non–small-cell lung cancer without disease progression after first-
line chemotherapy, were published previously. The objective of this 
report is to provide a mature analysis of overall survival (OS) for 
Iressa in NSCLC for maintenance study in intention to treat (ITT) 
population and in subgroups according to epidermal growth factor 
receptor (EGFR) mutation status.
Patients and Methods: A total of 296 patients were randomly 
assigned. EGFR mutations were detected using an amplification 
mutation refractory system. Seventy-nine patients were assessable 
for EGFR mutations. OS was analyzed by a Cox proportional haz-
ards model adjusted for the same covariates in ITT population and 
subgroups according to EGFR mutation status.
Results: OS was similar for gefitinib and placebo arm with no sig-
nificant difference between treatments in ITT population (hazard 
ratio [HR], 0.88; 95% confidence interval [CI], 0.68–1.14; p = 0.335) 
and in subgroups with wild type EGFR (HR, 1.27; 95% CI, 0.7–2.3; 
p = 0.431) or unknown EGFR mutations (HR, 0.92; 95% CI, 0.68, 
1.25; p = 0.603). In the EGFR mutation–positive subgroup, the 
gefitinib arm showed a higher OS than the placebo arm (HR, 0.39; 
95% CI, 0.15, 0.97; p = 0.036).
Conclusion: EGFR mutation was the strongest predictive biomarker 
for OS benefit of gefitinib as maintenance treatment. The analyses of 
OS showed that patients achieve a clear and significant survival ben-
efit if they receive EGFR tyrosine kinase inhibitors as maintenance 
treatment in EGFR mutation–positive patients.
 Key Words: Gefitinib, Maintenance, NSCLC, INFORM, OS.
(J Thorac Oncol. 2015;10: 655–664)
For patients with advanced non–small-cell lung cancer (NSCLC), platinum-based combination first-line che-
motherapy has been shown to prolong survival compared 
with best supportive care. However, the prognosis of these 
patients remains poor with a median survival time of 10 to 
12 months.1,2 Maintenance therapy is started immediately 
after first-line (induction) therapy and aims to prolong tumor 
response or stable disease (SD), thus improving progression-
free survival (PFS) and overall survival (OS), which is usu-
ally administered until disease progression or unacceptable 
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toxicity. Previous phase III trials have reported the effi-
cacy of maintenance therapy with minimal side effects for 
locally advanced or metastatic (stages IIIB–IV) NSCLC.3–6 
Switch maintenance, compared with continuation mainte-
nance, means using a different drug for maintenance therapy 
instead of using the one that is used for induction. Some 
studies have showed that switch maintenance could improve 
PFS and OS.7–10
The epidermal growth factor receptor (EGFR) is typical 
for an important signaling pathway that regulates tumorigen-
esis and cell survival and is frequently overexpressed in the 
development and progression of NSCLC.11,12 Previous studies 
have demonstrated the effectiveness of EGFR tyrosine kinase 
inhibitors (TKIs) as maintenance therapy.5,10,13–15 Recent data 
showed that EGFR mutations are a predictor of response to 
EGFR TKIs in patients.16–19 Patients with EGFR mutations 
have a significantly longer survival than those with wild-type 
EGFR when treated with EGFR TKIs.20,21
The Iressa in NSCLC FOR Maintenance study 
(INFORM; NCT00770588; C-TONG 0804) was a double-
blind, randomized, placebo-controlled, parallel-group study 
of gefitinib (250 mg/day) as maintenance therapy in patients 
from China with locally advanced/metastatic NSCLC who had 
achieved disease control after first-line platinum-based doublet 
chemotherapy. As previously reported,22 in INFORM trial, the 
primary end point of PFS was met and showed significantly 
longer PFS with gefitinib versus placebo overall (intention to 
treat [ITT]; HR, 0.42; 95% confidence interval [CI], 0.33–0.55; 
p < 0.0001; median PFS 4.8 vs. 2.6 months). In the subgroup 
of patients with EGFR mutation–positive tumor, PFS was sig-
nificantly longer for gefitinib versus placebo (HR, 0.17; 95% 
CI, 0.07–0.42; p = 0.0063; median PFS 16.6 vs. 2.8 months). 
Secondary end points, safety analysis, and early survival data 
were presented in 2012.22 Here, we report the final results of 
the survival analyses in the ITT population and in subgroups 
stratified by EGFR mutation from the INFORM study, on the 
FIGURE 1.  CONSORT diagram. †Cut off dates: June 17, 2014, for overall survival (OS) and progression-free survival. ‡All 
patients who were randomly assigned to a study group were included in the intent-to-treat analysis. ¶All patients who 
received at least one dose of study treatment were included in the safety analysis. ‖All patients in the intent-to-treat popula-
tion with an evaluable tumor sample.
657Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 4, April 2015 Final Overall Survival Results from INFORM Study
basis of 78% maturity and a follow-up period of up to 20.23 
months (median 17.83 months).
PATIENTS AND METHODS
Study Design and Treatment
Chinese patients with locally advanced/metastatic NSCLC 
who had achieved disease control after first-line platinum-based 
doublet chemotherapy were eligible. Full details of the INFORM 
have been published previously.22 Patients were randomized 1:1 
to gefitinib (250 mg/day orally) or placebo (orally) administered 
3–6 weeks postchemotherapy. Randomization was performed 
using dynamic balancing23 with respect to histology (adenocar-
cinoma [including bronchioalveolar carcinoma] vs. nonadeno-
carcinoma) and smoking history (never-smoker vs. ever-smoker; 
where never-smoker was defined as <100 cigarettes/lifetime). 
Treatment continued until objective disease progression, intol-
erable toxicity, dose delay/interruption for more than 14 days, 
withdrawal of consent, or serious noncompliance with study 
protocol. The primary end point of INFORM was superiority of 
gefitinib relative to placebo in terms of PFS. Objective response 
rate (ORR) and OS were secondary end points. Evaluation of 
tumor EGFR mutation status and efficacy of gefitinib versus pla-
cebo was a preplanned exploratory objective.
All patients provided written, informed consent, with 
separate consent obtained for optional provision of tumor 
material for biomarker analyses. Study approval was obtained 
from independent ethics committees at each institution. The 
study was conducted in accordance with the Declaration of 
Helsinki, the International Conference on Harmonization/
Good Clinical Practice, applicable regulatory requirements, 
and AstraZeneca’s policy on bioethics.
Assessments
OS was assessed from the date of randomization to death 
from any cause. In a supplementary analysis, OS was assessed 
from the date of induction chemotherapy to death from any 
cause. The provision of tumor samples (cytology samples 
were not permitted) for exploratory biomarker analysis was 
not mandated. Tumor EGFR mutation status was determined 
by analyzing DNA extracted from formalin-fixed and paraffin-
embedded archival tumor tissue at the AstraZeneca Innovation 
Centre China, Shanghai laboratory, using validated methods 
TABLE 1.  Demography and Baseline Characteristics in Intention to Treat Population and Subgroups Defined by EGFR 
Mutation Status
Category
ITT EGFR Positive 19(+) 21(+) EGFR Negative EGFR Unknown
Gefitinib 
(n = 148),  
n (%)
Placebo 
(n = 148),  
n (%)
Gefitinib 
(n = 10),  
n (%)
Placebo 
(n = 6),  
n (%)
Gefitinib 
(n = 5),  
n (%)
Placebo 
(n = 8),  
n (%)
Gefitinib 
(n = 25),  
n (%)
Placebo 
(n = 24),  
n (%)
Gefitinib 
(n = 108),  
n (%)
Placebo 
(n = 109),  
n (%)
Median age (range) 55 (31–79) 55 (20–75) 43 (32–59) 51 (40–64) 53 (46–65) 52 (33–75) 55 (31–72) 51 (35–62) 55 (37–79) 55 (20–74)
Gender
  Male 83 (56) 92 (62) 4 (40) 3 (50) 1 (20) 6 (75) 17 (68) 14 (58) 61 (56) 67 (61)
  Female 65 (44) 56 (38) 6 (60) 3 (50) 4 (80) 2 (25) 8 (32) 10 (42) 47 (44) 42 (39)
Histology type
  Adenocarcinoma 105 (71) 104 (70) 10 (100) 4 (67) 3 (60) 7 (88) 16 (64) 15 (63) 77 (71) 80 (74)
  Squamous 27 (18) 30 (20) 0 (0) 1 (17) 1 (20) 1 (13) 7 (28) 7 (29) 19 (18) 21 (19)
  Others 16 (11) 14 (10) 0 (0) 1 (17) 1 (20) 0 (0) 2 (8) 2 (8) 12 (11) 8 (7)
Disease stage
  IIIB 42 (39) 32 (30) 2 (20) 0 (0) 0(0) 1 (13) 6 (24) 7 (29) 34 (31) 24 (22)
  IV 106 (61) 116 (70) 8 (80) 6(100) 5(100) 7 (88) 19 (76) 17 (71) 74 (69) 85 (78)
WHO PS
  0 69 (47) 72 (49) 6 (60) 2 (33) 3 (60) 4 (50) 11 (44) 12 (50) 49 (45) 54 (50)
  1 76 (51) 72 (49) 3 (30) 4 (67) 2 (40) 4 (50) 14 (56) 11 (46) 57 (53) 52 (47)
  2 3 (2) 4 (3) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0) 1 (4) 2 (2) 3 (3)
Smoking history
  Nonsmoker 79 (53) 81 (55) 7 (70) 2 (33) 4 (80) 5 (63) 10 (40) 11 (46) 58 (54) 63 (58)
  Ex-smoker 57 (39) 55 (37) 3 (30) 4 (67) 0 (0) 2 (25) 13 (52) 11 (46) 41 (38) 37 (34)
  Current smoker 12 (8) 12 (8) 0 (0) 0 (0) 1 (20) 1 (13) 2 (8) 2 (8) 9 (8) 9 (8)
Type of first chemotherapy
  Taxane 60 (41) 66 (45) 7 (70) 3 (50) 4 (80) 5 (63) 13 (52) 10 (42) 36 (33) 48 (44)
  Nontaxane 88 (59) 82 (55) 3 (30) 3 (50) 1 (20) 3 (38) 12 (48) 14 (58) 72 (67) 61 (56)
Response to first chemotherapy
  PR or CR 58 (39) 51 (34) 1 (10) 2 (33) 2 (40) 4 (50) 11 (44) 10 (42) 44 (41) 35 (32)
  SD 90 (61) 97 (66) 9 (90) 4 (67) 3 (60) 4 (50) 14 (56) 14 (58) 64 (59) 74 (68)
EGFR, epidermal growth factor receptor; ITT, intent to treat; WHO PS, World Health Organization performance status; PR, partial response; CR, complete response; SD, stable disease.
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previously published by Fukuoka et al.24 Briefly, samples 
underwent central, histopathologic review; only those deemed 
suitable for downstream biomarker analysis were used for fur-
ther analysis (based on quality, sample source, and tumor con-
tent). EGFR mutations were detected using an amplification 
mutation refractory system-based EGFR mutation detection 
kit (DxS, Manchester, United Kingdom), with modified cut-
off values and conditions.24 Patients were considered EGFR 
mutation–positive if at least one of 29 EGFR mutations was 
detected24 (see Supplemental Table, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A766).
Statistical Analysis
In the ITT population (all randomized patients) and sub-
groups according to EGFR mutation status, the primary analysis 
compared OS with gefitinib versus placebo arm using a Cox pro-
portional hazards model adjusted for the same covariates as for the 
primary PFS analysis (histology, adenocarcinoma vs. nonadeno-
carcinoma, smoking history, never-smokers vs. smokers, tumor 
EGFR mutation status, positive vs. negative vs. unknown, and 
previous response to chemotherapy, complete response/partial 
response vs. SD). The hazard ratio (HR; gefitinib:placebo) was 
estimated with 95% CIs and p value. Final analysis of OS was 
planned when 230 deaths (78%) had occurred in the ITT popula-
tion and when the same level of maturity was reached for PFS.
RESULTS
Patients
From September 26, 2008 to August 10, 2009, 296 patients 
from 27 centers across China were randomized to gefitinib or 
placebo arm (ITT; n = 148 both arms). Patient disposition is pre-
sented in Figure 1. For the ITT population, demographics and 
baseline characteristics are presented in Table 1. Poststudy treat-
ments by study arms in the overall population and in different 
EGFR mutation status subgroups are listed in Table 2.
OS (ITT Population)
The median duration of follow up for OS was 17.83 
months (95% CI, 15.43–20.23). At the time of data cutoff for 
OS (June 17, 2014), 230 patients (78%) had died (Fig. 1). In the 
overall population, OS was similar for gefitinib and placebo with 
no significant difference between the two arms (112 and 118 
events, respectively; HR, 0.88; 95% CI, 0.68–1.14; p = 0.335; 
median OS for gefitinib, 18.97 months vs. 16.00 months for 
placebo; Fig. 2A). A consistent effect of maintenance treatment 
with gefitinib was seen across all clinical subgroups, with the 
exception of EGFR mutation–positive subgroups (Fig. 3).
Subgroup Analyses
Of the 296 patients enrolled, 102 patients (34.5%) pro-
vided tissue samples for biomarker analyses, of which 23 were 
unsuitable for analysis due to insufficient quantity/quality 
as determined after pathologic review. A total of 79 (26.7%) 
samples were assessable for EGFR mutations, with 30 patients 
(38%) presenting with EGFR mutation–positive tumors. 
EGFR mutations detected in tumor tissue samples are sum-
marized in Table (Supplemental Digital Content 1, http://links.
lww.com/JTO/A766). For patients in subgroups stratified by 
EGFR mutation status, demographics and baseline characteris-
tics were generally comparable to the ITT population (Table 1) 
and were also balanced between the treatment arms.
In the subgroup positive for EGFR mutation, a higher 
OS was observed in patients treated with gefitinib than that 
in the placebo arm (HR, 0.39; 95% CI, 0.15, 0.97; p = 0.036; 
median OS, 46.87 vs. 20.97 months; Fig. 2B). By contrast, 
TABLE 2.  Summary of Poststudy Treatments by Study Arms in the Overall Population and in EGFR Mutation Status Subgroups 
(ITT Population; Data from OS Data Cutoff)
Treatment
ITT Population EGFR Mutation Positive EGFR Mutation Negative EGFR Mutation Unknown
Gefitinib, 
n (%)
Placebo, 
n (%)
Gefitinib, 
n (%)
Placebo, 
n (%)
Gefitinib, 
n (%)
Placebo, 
n (%)
Gefitinib, 
n (%)
Placebo,  
n (%)
Still in study 4 (3) 1 (1) 1 (7) 0 (0) 0 (0) 0 (0) 3 (3) 1 (1)
None 38 (26) 23 (16) 3 (20) 2 (13) 5 (20) 5 (21) 30 (28) 16 (15)
Chemotherapy only 65 (44) 54 (36) 4 (27) 4 (27) 14 (56) 7 (29) 47 (44) 43 (39)
Taxane 39 34 1 3 10 6 28 25
Nontaxane 21 17 3 1 4 1 14 15
Not-clear 5 3 0 0 0 0 5 3
EGFR TKIs involved 15 (10) 53 (36) 3 (20) 8 (53) 3 (12) 8 (33) 9 (8) 37 (34)
Gefitinib 8 30 0 3 1 3 7 24
Erlotinib 6 18 3 3 2 5 1 10
Other EGFR TKIs 1 5 0 2 0 0 1 3
Radiotherapy only 5 (3) 5 (3) 0 (0) 0 (0) 2 (8) 1 (4) 3 (3) 4 (4)
Lost to follow-up 21 (14) 12 (8) 4 (27) 1 (7) 1 (4) 3 (13) 16 (15) 8 (7)
Total 148 148 15 15 25 24 108 109
A patient may appear in more than one poststudy treatment group. Patients may have received the same second-line and third-line therapies.
“None” is defined as patients who did not receive any form of cancer treatment after discontinuation of randomly assigned treatment. Radiotherapy, surgery, medical procedures, 
and other treatments were excluded.
ITT, intent to treat; OS, overall survival; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
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there was no significant difference in OS for gefitinib versus 
placebo in patients negative for EGFR mutations (HR, 1.27; 
95% CI, 0.7–2.3; p = 0.431; median OS, 10.9 vs. 14.0 months; 
Fig. 2C). In the subgroup with unknown EGFR mutation, OS 
was numerically but not statistically longer with gefitinib ver-
sus placebo (HR, 0.92; 95% CI, 0.68, 1.25; p = 0.603; median 
OS, 20.6 vs. 16.8 months; Fig. 2D).
Exploratory Analysis: Impact of Subsequent 
EGFR TKIs Treatments on OS
Treatments after discontinuation of trial in the ITT pop-
ulation are presented in Table 2. We observed no significant 
differences between the two treatment arms in patients treated 
with chemotherapy poststudy. However, in the placebo arm, a 
higher rate of patients (36%) received EGFR TKIs treatment 
after discontinuation of the study compared with patients in 
study arm (10%, p = 0.001).
To assess the effect of subsequent EGFR TKIs treatment 
on OS, we divided patients into two groups. Group A included 
patients who received EGFR TKIs as either maintenance or subse-
quent treatment, whereas group B included patients who had never 
received any EGFR TKIs during the treatment process before ran-
domization into the study. We examined demographic factors and 
rates of subsequent chemotherapy used in these two treatment 
FIGURE 2 Kaplan–Meier curves for overall survival in the overall population and by epidermal growth factor receptor (EGFR) 
mutation status (intent-to-treat population). Hazard ratio less than 1 implies a lower risk of death for patients treated with gefi-
tinib. A, Overall population. B, Patients with EGFR mutation–positive tumors. C, Patients with EGFR mutation-negative tumors. 
D, Patients with EGFR mutation status unknown tumors.
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groups. Both treatment groups exhibited similar demographics 
and rates of subsequent chemotherapy (Table 3). However, we did 
observe a significantly longer OS for patients in group A than in 
group B (HR, 0.66; 95% CI, 0.50–0.88; p = 0.004; median OS, 
19.9 vs. 14.7 months; Fig. 4A). Significant difference in OS was 
also observed in the subgroup of patients who were positive for 
EGFR mutations (HR, 0.40; 95% CI, 0.16–1.00; median OS, 38.4 
vs. 19.3 months; Fig. 4B). In the subgroup whose EGFR mutation 
status is unknown, patients receiving TKIs either as maintenance 
or as subsequent had a lower risk of death compared with patients 
who did not receive TKIs since maintenance (HR, 0.68; 95% CI, 
0.49–0.88). A similar OS benefit was seen across most of the sub-
groups, with the exception of male, nonadenocarcinoma, smoker 
and EGFR mutation–negative subgroups (Fig. 5).
DISCUSSION
INFORM was the first phase III randomized mainte-
nance study to be conducted solely in patients from East Asian 
with advanced NSCLC. Previous reports showed significantly 
longer PFS, higher ORR and disease control rate, and better 
symptomatic control with gefitinib than placebo. However, 
maintenance gefitinib therapy showed no survival benefit over 
placebo based on a survival analysis of 59% (176 of 296) of 
deaths events.22
Unfortunately in current report, with a more mature 
follow-up data, longer PFS was not associated with the differ-
ence in OS between the two treatment arms in the ITT popula-
tion. The final OS analyses of INFORM trial were consistent 
with previous studies reporting on maintenance treatment.5,13,14 
Gaafar et al.14 reported a phase III study (EORTC 08021) of 
similar design to INFORM that found no statistical signifi-
cance in OS (primary end point) in Caucasians (median fol-
low up of 41 months; HR, 0.83; 95% CI, 0.60–1.15; p, 0.2; 
median survival for gefitinib and placebo, 10.9 vs. 9.4 months, 
respectively). Furthermore, in a randomized Japanese phase III 
WJTOG0203 study,13 OS (primary end point) was not statisti-
cally different in patients treated with gefitinib or on placebo 
FIGURE 3.  Forest plot of overall sur-
vival by clinical subgroup and epider-
mal growth factor receptor mutation 
status (intent-to-treat population). 
Hazard ratio less than 1 implies 
a lower risk of death for patients 
treated with gefitinib. The size of the 
point estimate reflects the number of 
events in the subgroup, with a larger 
circle indicating more events. Cox 
analysis with covariates (histology 
[adenocarcinoma vs. nonadenocar-
cinoma]; World Health Organization 
performance status [0, 1, vs. 2]; 
smoking history [never-smokers vs. 
smokers]; tumor epidermal growth 
factor receptor mutation status [posi-
tive vs. negative vs. unknown]; type 
of first-line chemotherapy [taxane 
vs. nontaxane]; previous response to 
chemotherapy [complete or partial 
response vs. stable disease]; sex; and 
disease stage at screening [IIIb vs. 
IV]). CR, complete response; PR, par-
tial response; SD, stable disease; OS, 
overall survival; HR, hazard ratio.
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(78% maturity, HR, 0.86; 95% CI, 0.72, 1.03; p = 0.11; median 
survival for chemotherapy followed by gefitinib and chemo-
therapy alone, 13.7 vs. 12.9 months, respectively). The phase 
III study of IFCT-GFPC 05025 also demonstrated that main-
tenance treatment with erlotinib was not statistically different 
from the observation group (HR, 0.87; 95% CI, 0.68, 1.13; 
p = 0.3043; median survival for erlotinib and observation, 11.4 
vs. 10.8 months, respectively). Clearly, our study results, com-
bined with other similar studies, do not support the routine use 
of gefitinib for maintenance treatment as standard of care in all 
advanced NSCLC patients who achieved disease control after 
treatment with platinum-based chemotherapy.
Previous studies25–27 have demonstrated that EGFR 
mutation status is a strong predictor for treatment response. 
In IPASS26 and First-SIGNAL27 studies, molecular analyses 
suggested that the benefit of gefitinib was limited to patients 
exhibiting EGFR mutations. In this study, a significant pro-
longation of PFS in EGFR mutation–positive subgroup of the 
gefitinib arm was observed, which was associated with a sig-
nificantly longer OS compared with placebo (HR, 0.39; 95% 
CI, 0.15, 0.97; p = 0.036). Because of the lack of subgroup 
analyses based on EGFR mutation status from previous gefi-
tinib maintenance studies,13,14 we could not make direct com-
parisons in the INFORM IPASS, NEJ002 study. SATURN 
study28 had the same design as INFORM, but the recent bio-
marker analysis of the SATURN study10 failed to report the 
OS benefit for patients with EGFR mutation–positive tumors, 
probably due to the high degree of censoring and the 67% 
crossover rate to second-line EGFR TKI therapy in the pla-
cebo group for this population. In the INFORM study, the 
subgroup with EGFR mutation–positive tumors had a cross-
over rate of 53% (8 of 15). Reviewing first-line trials,19,24,29 
which failed to find improved OS for patients with EGFR 
mutation–positive, the crossover rate in IPASS, NEJ002, 
and the European Tarceva versus Chemotherapy (EURTAC) 
study was 64.3%, 95%, and 76%, respectively. In the present 
study, although the number of tumor samples evaluable for 
EGFR mutation status was small, it is notable that median 
OS was 46.87 months in the gefitinib maintenance arm com-
pared with 20.97 months in placebo (p = 0.036). Our study 
indicated that EGFR mutation is an important predictor of 
OS in patients treated with gefitinib for maintenance com-
pared with placebo, so our data emphasize the importance 
of selecting patients who could benefit from EGFR TKIs by 
EGFR genetic testing, especially in an Asian lung cancer 
population. As we know, the current standard of care is to test 
EGFR mutation first and to give EGFR TKIs as front line if 
the result for EGFR mutation testing is positive. However, if 
mutation testing results are unavailable for whatever reason, 
the chemotherapy had been employed initially, for patients 
whose tumors have confirmed EGFR activating mutations 
and have achieve partial response/SD response from first-line 
chemotherapy, and EGFR TKIs should be used as mainte-
nance therapy on the basis of this study.
Subsequent treatments that patients received are likely 
to have confounding effects when evaluating the OS of 
patients on first line or maintenance treatment. Our previous 
meta-analysis of East Asian patients30 showed that advanced 
NSCLC patients treated with both platinum-based doublet 
chemotherapy and EGFR-TKIs in any order were superior 
to chemotherapy alone. In this study, higher incidence of 
EGFR mutations was observed in the East Asian population 
compared with patients of other ethnicities; we also observed 
that more patients in the placebo arm received subsequent 
therapy (84%) compared with patients in the gefitinib arm 
(74%) (p = 0.031, Table 2). Further analysis showed that 
although chemotherapy/radiotherapy used in the poststudy 
setting is similar between the two treatment arms (Table 2), 
there was a difference in the use of EGFR TKIs, which could 
affect OS. Therefore, we conducted an exploratory analysis 
based on whether the patient received EGFR TKIs treatment 
or not after randomization. We found that patients receiving 
EGFR TKIs as maintenance or subsequent treatment had a 
longer OS than patients who never received any EGFR TKIs 
in the ITT population. Furthermore, most of the clinical 
TABLE 3.  Demography and Baseline Characteristics 
in Patients Defined by the Usage of EGFR TKIs since 
randomization
Characteristics
Patients Treatment from Randomization 
(%)
TKIs  
Treatmenta
No TKIs  
Treatmentb P
All patients 201 83
Gender
  Male 118 (59) 48 (58) 0.892
  Female 83 (41) 35 (42)
Histology type
  Adenocarcinoma 145 (72) 57 (69) 0.558
  Nonadenocarcinoma 56 (28) 26 (31)
Disease stage
  IIIB 52 (26) 18 (22) 0.457
  IV 149 (74) 65 (78)
WHO PS
  0 96 (48) 37 (45) 0.625
  1 or 2 105 (52) 46 (55)
Smoking history
  Never 106 (53) 48 (58) 0.433
  Smoker 95 (47) 35 (42)
Type of first chemotherapy
  Taxane 83 (41) 34 (41) 0.959
  Nontaxane 118 (59) 49 (59)
Response to first chemotherapy
  PR or CR 81 (40) 25 (30) 0.107
  SD 120 (60) 58 (70)
EGFR mutation status
  Positive 23 (11) 7 (8) 0.701
  Negative 33 (16) 13 (16)
  Unknown 145 (72) 64 (77)
aTKIs treatment indicates patients received EGFR TKIs as maintenance or 
subsequent treatment since randomization.
bNo TKIs treatment indicates patients never received any EGFR TKIs since 
randomization.
EGFR, epidermal growth factor receptor; WHO PS, World Health Organization 
performance status; PR, partial response; CR, complete response; SD, stable disease.
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subgroups, such as female, adenocarcinoma, nonsmoker 
and EGFR mutation–positive subgroups, but not in EGFR-
mutation negative subgroup, also demonstrated a longer OS. 
Although this exploratory analysis was an unplanned sub-
group analysis, our observations of the effects of OS based 
on subsequent EGFR TKIs treatment are consistent with our 
previous meta-analysis and OPTIMAL study.31 In addition, 
we are aware of the limitations of this exploratory analysis, 
a small number of patients (23%,16 of 148) in placebo arm 
did not received any subsequent treatment, some of them 
may die early and lose their chance to receive EGFRTKIs or 
chemotherapy, thus the OS results could be affected. Larger 
phase III trials are needed to evaluate the effects of subse-
quent treatment on OS for this subpopulation of patients.
In this study, patients in the gefitinib arm demon-
strated a numerically longer OS than patients in the placebo 
FIGURE 4.  Kaplan–Meier curves for overall 
survival in the overall population and epider-
mal growth factor receptor (EGFR) mutation 
subgroup. Hazard ratio less than 1 implies 
a lower risk of death for patients treated 
with gefitinib. EGFR-TKI involved means 
patients received EGFR TKIs as maintenance 
or subsequent treatment since randomiza-
tion; without EGFR TKI means patients never 
received any EGFR TKIs since randomization. 
A, Overall population. B, Patients with EGFR 
mutation–positive tumors.
663Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 4, April 2015 Final Overall Survival Results from INFORM Study
arm (median OS for gefitinib, 18.97 vs. 16.00 months for 
placebo). Because of the relative low number of patients 
included in our study significant differences between the 
two treatment arms were not observed. In the exploratory 
analysis, of the ITT population randomly assigned to the 
placebo arm, 36% (53 of 148) of patients received EGFR 
TKIs as subsequent therapy, which is significantly higher 
than study arm (10%, 15 of 148; p = 0.001) and may be a 
reason why no difference in OS was observed. In addition, 
no molecular selection for patient’s enrolment in our study 
can be another explanation for the absence of OS benefit. 
When we initiated this double-blind, randomized trial, the 
clinical advantage of large-scale screening for EGFR muta-
tions in patients with NSCLC had not been emphasized in 
Asian and in the world, we did not select patients by EGFR 
mutation status, and the collection of tumor material was 
not mandatory or feasible in all patients, so INFORM has 
big proportion of patients without tumor samples (73%). 
But it is worth to know that East-Asian patients have greater 
frequency of EGFR mutations compared with Caucasia 
patients,16,32,33 almost one in three East-Asian patients could 
have EGFR mutation, and therefore, could benefit from 
EGFR TKI therapy. Nevertheless, the INFORM study does 
demonstrate the unprecedented median OS (exceeding 
18 months) in gefitinib arm compared with previous switch 
maintenance studies,3,5,10,13,14 indicating further exploration 
into this treatment strategy is warranted, especially in EGFR 
mutation–positive population.
In summary, the final OS analysis of the INFORM data 
confirms the PFS finding, which translates into a significant 
OS benefit for patients with EGFR mutation–positive tumors, 
but not for patients with EGFR mutation–negative or unknown. 
EGFR mutation was the strongest predictive biomarker for ben-
efit of gefitinib over placebo on PFS, ORR, and OS. Patients 
receiving EGFR TKIs as maintenance or subsequent treatment 
had longer OS than patients who had never received any EGFR 
TKIs (overall and EGFR mutation–positive subgroups). The 
positive results from INFOM, together with those from other 
maintenance therapy studies, demonstrated that gefitinib in the 
maintenance setting leads to significantly improved outcomes 
for patients with EGFR-mutated advanced NSCLC.
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FIGURE 5.  Forest plot of overall sur-
vival (OS) in two groups by clinical 
subgroup and epidermal growth fac-
tor receptor (EGFR) mutation status 
(intent-to-treat population). Hazard 
ratio less than 1 implies a lower risk 
of death for patients treated with 
gefitinib. The size of the point esti-
mate reflects the number of events 
in the subgroup, with a larger circle 
indicating more events. Cox analysis 
with covariates (histology [adeno-
carcinoma vs. nonadenocarcinoma]; 
World Health Organization perfor-
mance status [0, 1, vs. 2]; smoking 
history [never-smokers vs. smokers]; 
tumor EGFR mutation status [posi-
tive vs. negative vs. unknown]; type 
of first-line chemotherapy [taxane 
vs. nontaxane]; previous response to 
chemotherapy [complete or partial 
response vs. stable disease]; sex; 
and disease stage at screening [IIIb 
vs. IV]). CR, complete response; PR, 
partial response; SD, stable disease; 
OS, overall survival since randomiza-
tion; HR, hazard ratio; TKIs, patients 
received EGFR TKIs as maintenance 
or subsequent treatment since 
randomization; no TKIs, patients 
never received any EGFR TKIs since 
randomization.
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